WASHINGTON, Dec 13 (Reuters) - U.S. regulatory staff need more information from Merck & Co. Inc. (MRK.N: Quote, Profile, Research) before they can finish reviewing the effectiveness of an experimental vaccine to help prevent severe diarrhea in children, according to documents released on Tuesday.